Floatz logo

Omnipaque

ER Positive Breast Cancer

Jennifer Lee Caswell-JinPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

77 Active assets in the ER Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Abemaciclib
Jonsson Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Omnipaque is also rated in:

Adolescent ObesityDormant
CCC
Indicative ·
52 / 100
View asset →
Diabetic Kidney DiseaseDormant
CCC
Indicative ·
52 / 100
View asset →
Diabetes ComplicationsDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →